Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ
Market Cap
$183.44M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
663 of 968
Rank in Industry
371 of 556
Largest Insider Buys in Sector
ENTA Stock Price History Chart
ENTA Stock Performance
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Insider Activity of Enanta Pharmaceuticals, Inc.
Over the last 12 months, insiders at Enanta Pharmaceuticals, Inc. have bought $0 and sold $605,204 worth of Enanta Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Enanta Pharmaceuticals, Inc. have bought $0 and sold $2.77M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $24,445 was made by Gardiner Nathaniel S. (Sr. VP & General Counsel) on 2016‑05‑11.
List of Insider Buy and Sell Transactions, Enanta Pharmaceuticals, Inc.
| 2024-07-15 | Sale | Chief Medical Officer | 5,375 0.0355% | $17.08 | $91,805 | 0.00% | ||
| 2024-07-12 | Sale | Chief Medical Officer | 2,271 0.0132% | $15.04 | $34,156 | 0.00% | ||
| 2024-07-11 | Sale | Chief Medical Officer | 4,299 0.0251% | $15.07 | $64,786 | 0.00% | ||
| 2024-06-17 | Sale | Chief Product Strategy Officer | 7,266 0.0315% | $12.33 | $89,590 | -2.15% | ||
| 2023-12-13 | Sale | director | 15,295 0.0684% | $9.12 | $139,490 | +28.58% | ||
| 2023-12-05 | Sale | President and CEO | 7,230 0.0351% | $9.63 | $69,625 | +31.12% | ||
| 2023-12-05 | Sale | Sr. VP, R&D & CSO | 2,412 0.0117% | $9.63 | $23,228 | +31.12% | ||
| 2023-12-05 | Sale | Sr. VP, Finance & Admin. & CFO | 2,412 0.0117% | $9.63 | $23,228 | +31.12% | ||
| 2023-12-05 | Sale | Sr. VP & General Counsel | 2,412 0.0117% | $9.63 | $23,228 | +31.12% | ||
| 2023-12-05 | Sale | Sr. VP, New Prod. Strat. & Dev | 2,125 0.0103% | $9.63 | $20,464 | +31.12% | ||
| 2023-12-05 | Sale | Sr. VP, Business Dev. | 2,125 0.0103% | $9.63 | $20,464 | +31.12% | ||
| 2023-12-05 | Sale | Sr. VP & CMO | 534 0.0026% | $9.63 | $5,142 | +31.12% | ||
| 2023-03-15 | Sale | Sr. VP & CSO | 13,925 0.0661% | $44.45 | $618,960 | -67.56% | ||
| 2023-03-15 | Sale | Treasurer and CFO | 10,440 0.0495% | $44.43 | $463,802 | -67.56% | ||
| 2023-03-13 | Sale | President and CEO | 27,912 0.133% | $45.16 | $1.26M | -67.30% | ||
| 2023-02-09 | Sale | Treasurer and CFO | 5,000 0.0241% | $53.76 | $268,816 | -70.01% | ||
| 2022-12-16 | Sale | President and CEO | 30,000 0.1421% | $44.72 | $1.34M | -48.24% | ||
| 2022-04-01 | Sale | Sr. VP & Chief Medical Officer | 18,076 0.0872% | $71.71 | $1.3M | -31.68% | ||
| 2022-03-21 | Sale | 2,676 0.0131% | $66.70 | $178,489 | -25.35% | |||
| 2022-03-02 | Sale | Sr. VP & Chief Medical Officer | 12,481 0.0609% | $70.07 | $874,544 | -27.80% |
Insider Historical Profitability
11.84%
| Luly Jay R. | President and CEO | 806793 3.8067% | $8.66 | 0 | 17 | |
| Or Yat Sun | Sr. VP, R&D & CSO | 370695 1.749% | $8.66 | 0 | 18 | |
| MELLETT PAUL J | Sr. VP, Finance & Admin. & CFO | 93549 0.4414% | $8.66 | 0 | 20 | |
| Gardiner Nathaniel S. | Sr. VP & General Counsel | 68154 0.3216% | $8.66 | 3 | 2 | +9.2% |
| Luu Brendan | Sr. VP, Business Dev. | 36736 0.1733% | $8.66 | 0 | 1 | |
| Kieffer Tara Lynn | Chief Product Strategy Officer | 32341 0.1526% | $8.66 | 0 | 2 | |
| Rottinghaus Scott T. | Chief Medical Officer | 21717 0.1025% | $8.66 | 0 | 4 | |
| Vance Terry | director | 5800 0.0274% | $8.66 | 2 | 1 | +8.96% |
| Goldberg Marc E. | director | 547606 2.5837% | $8.66 | 0 | 3 | |
| SCHUHSLER HELMUT | 380487 1.7952% | $8.66 | 1 | 3 | +19.31% | |
| TVM V LIFE SCIENCE VENTURES GMBH & CO KG | 10 percent owner | 276999 1.307% | $8.66 | 1 | 7 | +19.31% |
| Adda Nathalie | Sr. VP & Chief Medical Officer | 47191 0.2227% | $8.66 | 0 | 14 | |
| AFTING ERNST-GUENTER | director | 17287 0.0816% | $8.66 | 0 | 1 | |
| SAINTS CAPITAL GRANITE, L.P. | 10 percent owner | 16904 0.0798% | $8.66 | 1 | 8 | +19.31% |
| Ocain Tim | Senior Vice President | 6127 0.0289% | $8.66 | 0 | 1 | |
| CARTER BRUCE L A | 3324 0.0157% | $8.66 | 0 | 4 | ||
| Verdine Gregory L. | director | 3324 0.0157% | $8.66 | 1 | 0 | +19.31% |
| Buckley Stephen Jr. | director | 2000 0.0094% | $8.66 | 3 | 0 | +6.42% |
| Golumbeski George | director | 0 0% | $8.66 | 0 | 3 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Farallon Capital | $36.58M | 9.89 | 2.1M | +3.46% | +$1.22M | 0.26 | |
| Morgan Stanley | $35.71M | 9.66 | 2.05M | +74.34% | +$15.23M | <0.01 | |
| The Vanguard Group | $33.66M | 9.1 | 1.93M | +7.49% | +$2.34M | <0.01 | |
| BlackRock | $32.11M | 8.68 | 1.84M | -4.94% | -$1.67M | <0.01 | |
| Armistice Capital Llc | $21.58M | 5.84 | 1.24M | -40.12% | -$14.46M | 0.07 | |
| Krensavage Asset Management LLC | $19.64M | 5.31 | 1.12M | +51.39% | +$6.67M | 9.91 | |
| Marshall Wace | $16.61M | 4.49 | 951,062 | New | +$16.61M | 0.02 | |
| Northern Trust | $16.3M | 4.41 | 933,356 | -0.23% | -$37,312.02 | <0.01 | |
| Caligan Partners LP | $14.98M | 4.05 | 858,070 | New | +$14.98M | 3.96 | |
| Acadian Asset Management | $14.91M | 4.03 | 853,896 | +1.3% | +$191,183.13 | 0.05 | |
| Millennium Management LLC | $12.33M | 3.34 | 706,248 | -7.7% | -$1.03M | 0.01 | |
| Assenagon Asset Management S.A. | $10.19M | 2.76 | 583,658 | 0% | +$0 | 0.03 | |
| Soleus Capital Management, L.P. | $10.14M | 2.74 | 580,546 | New | +$10.14M | 0.04 | |
| D. E. Shaw & Co. | $9.96M | 2.69 | 570,246 | -10.64% | -$1.19M | 0.01 | |
| Renaissance Technologies | $9.19M | 2.48 | 526,100 | -5.8% | -$565,722.11 | 0.02 | |
| Bank of America | $9.02M | 2.44 | 516,366 | +4,111.79% | +$8.8M | <0.01 | |
| Geode Capital Management | $7.72M | 2.09 | 442,072 | +2.99% | +$224,124.97 | <0.01 | |
| State Street | $7.4M | 2 | 423,965 | -0.39% | -$29,245.50 | <0.0001 | |
| Boothbay Fund Management LLC | $6.78M | 1.84 | 388,600 | New | +$6.78M | 0.22 | |
| Tang Capital Management, LLC | $5.24M | 1.42 | 300,000 | 0% | +$0 | 0.02 | |
| Two Sigma Advisers LP | $4.92M | 1.33 | 282,000 | -3.03% | -$153,648.00 | 0.01 | |
| Two Sigma | $4.49M | 1.22 | 257,309 | -22.55% | -$1.31M | 0.01 | |
| Ubs Asset Management Americas Inc | $3.63M | 0.98 | 208,089 | -7.13% | -$279,010.80 | <0.01 | |
| Jacobs Levy Equity Management | $3.4M | 0.92 | 194,730 | -65.29% | -$6.4M | 0.01 | |
| Dimensional Fund Advisors | $3.3M | 0.89 | 189,256 | +5.4% | +$169,239.74 | <0.01 | |
| Sio Capital Management LLC | $3.09M | 0.84 | 177,004 | New | +$3.09M | 1.11 | |
| Prudential Financial | $3.01M | 0.81 | 172,264 | -11% | -$371,897.95 | <0.01 | |
| Charles Schwab | $2.81M | 0.76 | 161,000 | +9.28% | +$238,660.74 | <0.01 | |
| JPMorgan Chase | $2.41M | 0.65 | 138,047 | -8.47% | -$223,034.08 | <0.0001 | |
| AQR Capital | $1.92M | 0.52 | 109,706 | -46.03% | -$1.63M | <0.01 | |
| Qube Research & Technologies | $1.79M | 0.49 | 102,625 | -45.65% | -$1.51M | <0.01 | |
| Trexquant Investment LP | $1.67M | 0.45 | 95,639 | -19.37% | -$401,108.59 | 0.03 | |
| Goldman Sachs | $1.58M | 0.43 | 90,690 | -51.41% | -$1.68M | <0.0001 | |
| Nuveen | $1.56M | 0.42 | 89,387 | +60.75% | +$589,798.79 | <0.0001 | |
| SEI Investments Company | $1.54M | 0.42 | 88,155 | 0% | +$0 | <0.01 | |
| Federated Hermes | $1.54M | 0.42 | 88,172 | -33.8% | -$785,996.76 | <0.01 | |
| BNY Mellon | $1.14M | 0.31 | 65,196 | -10.23% | -$129,727.33 | <0.0001 | |
| Citadel Advisors LLC | $970,130.00 | 0.26 | 55,563 | -16.38% | -$190,017.18 | <0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $779,222.00 | 0.21 | 44,629 | +7.89% | +$56,989.42 | <0.01 | |
| Invesco | $759,492.00 | 0.21 | 43,499 | +115% | +$406,241.53 | <0.0001 | |
| PDT Partners | $693,633.00 | 0.19 | 39,727 | -37.17% | -$410,274.83 | 0.05 | |
| Fidelity Investments | $688,291.00 | 0.19 | 39,421 | +28.55% | +$152,879.84 | <0.0001 | |
| Pennant Capital Management Llc | $612,846.00 | 0.17 | 35,100 | 0% | +$0 | 0.1 | |
| RhumbLine Advisers | $576,479.00 | 0.16 | 33,018 | +2.18% | +$12,291.51 | <0.01 | |
| Ameriprise Financial | $556,503.00 | 0.15 | 31,873 | -65.95% | -$1.08M | <0.0001 | |
| Franklin Templeton Investments | $507,493.00 | 0.14 | 29,066 | New | +$507,493.00 | <0.0001 | |
| AllianceBernstein | $487,658.00 | 0.13 | 27,930 | 0% | +$0 | <0.0001 | |
| Cubist Systematic Strategies | $477,483.00 | 0.13 | 27,347 | -66.96% | -$967,642.08 | <0.01 | |
| Point72 Asia Singapore Pte Ltd | $440,163.00 | 0.12 | 25,210 | +2,000.83% | +$419,211.17 | 0.04 | |
| Wells Fargo | $434,910.00 | 0.12 | 24,909 | +303.19% | +$327,042.40 | <0.0001 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.